{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:22:17Z","timestamp":1775323337608,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40120-024-00697-4","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:43:45Z","timestamp":1740055425000},"page":"627-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures in a Real-Life Setting: A Prospective, Observational Study in Europe"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-5862","authenticated-orcid":false,"given":"Bernhard J.","family":"Steinhoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin P.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Majoie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Liv","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Bourikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Leunikava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kelemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-987X","authenticated-orcid":false,"given":"Eduardo","family":"Rubio-Nazabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"697_CR1","unstructured":"UCB Pharma SA: Summary of product characteristics Briviact\u00ae (Europe). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/briviact-epar-product-information_en.pdf (2024). Accessed 9 July 2024."},{"key":"697_CR2","unstructured":"UCB Inc.: BRIVIACT\u00ae (brivaracetam) prescribing information. https:\/\/www.briviact.com\/briviact-PI.pdf (2023). Accessed 9 July 2024."},{"issue":"1","key":"697_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/epi.12433","volume":"55","author":"V Biton","year":"2014","unstructured":"Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57\u201366.","journal-title":"Epilepsia"},{"issue":"12","key":"697_CR4","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/epi.13212","volume":"56","author":"P Klein","year":"2015","unstructured":"Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890\u20138.","journal-title":"Epilepsia"},{"issue":"1","key":"697_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/epi.12432","volume":"55","author":"P Ryvlin","year":"2014","unstructured":"Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47\u201356.","journal-title":"Epilepsia"},{"issue":"4","key":"697_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/ane.13059","volume":"139","author":"V Villanueva","year":"2019","unstructured":"Villanueva V, L\u00f3pez-Gonz\u00e1lez FJ, Mauri JA, Rodriguez-Uranga J, Oliv\u00e9-Gadea M, Montoya J, et al. BRIVA-LIFE\u2013a multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand. 2019;139(4):360\u20138.","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"697_CR7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40263-021-00856-3","volume":"35","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Chiesa V, Dainese F, et al. Adjunctive brivaracetam in focal epilepsy: real-world evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). CNS Drugs. 2021;35(12):1289\u2013301.","journal-title":"CNS Drugs"},{"key":"697_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106329","volume":"165","author":"BJ Steinhoff","year":"2020","unstructured":"Steinhoff BJ, Christensen J, Doherty CP, Majoie M, De Backer M, Hellot S, et al. Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: second interim analysis of 6-month data from a prospective observational study in Europe. Epilepsy Res. 2020;165:106329.","journal-title":"Epilepsy Res"},{"issue":"4","key":"697_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4082\/kjfm.2013.34.4.227","volume":"34","author":"SY Kim","year":"2013","unstructured":"Kim SY. Efficacy versus effectiveness. Korean J Fam Med. 2013;34(4):227.","journal-title":"Korean J Fam Med"},{"key":"697_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00698-3","author":"E Rubio-Nazabal","year":"2025","unstructured":"Rubio-Nazabal E, Majoie M, Schulz AL, Brock F, Leunikava I, Bourikas D, et al. Health-related quality of life and cognitive performance during 12-month adjunctive brivaracetam treatment in patients with focal-onset seizures: a prospective, observational study in Europe. Neurol Ther. 2025. https:\/\/doi.org\/10.1007\/s40120-024-00698-3","journal-title":"Neurol Ther"},{"key":"697_CR11","doi-asserted-by":"crossref","unstructured":"Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22(4):489\u2013501.","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"issue":"4","key":"697_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):522\u201330.","journal-title":"Epilepsia"},{"key":"697_CR13","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology: ATC\/DDD Index 2015. http:\/\/www.whocc.no\/atc_ddd_index\/ (2015). Accessed 3 November 2015."},{"key":"697_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107207","volume":"197","author":"S Stern","year":"2023","unstructured":"Stern S, Weingarten M, Mandapati S, Ferrari L, Wade CT. Real-world analysis of retention on cenobamate in patients with epilepsy in the United States. Epilepsy Res. 2023;197:107207.","journal-title":"Epilepsy Res"},{"issue":"4","key":"697_CR15","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s00415-021-10751-y","volume":"269","author":"V Villanueva","year":"2022","unstructured":"Villanueva V, D\u2019Souza W, Goji H, Kim DW, Liguori C, McMurray R, et al. PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice. J Neurol. 2022;269(4):1957\u201377.","journal-title":"J Neurol"},{"issue":"7","key":"697_CR16","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/epi.13416","volume":"57","author":"M Toledo","year":"2016","unstructured":"Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016;57(7):1139\u201351.","journal-title":"Epilepsia"},{"issue":"9","key":"697_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40263-023-01033-4","volume":"37","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Laloyaux C, D\u2019Souza W, Faught E, Klein P, Reuber M, et al. Effectiveness and tolerability of 12-month brivaracetam in the real world: EXPERIENCE, an international pooled analysis of individual patient records. CNS Drugs. 2023;37(9):819\u201335.","journal-title":"CNS Drugs"},{"issue":"1","key":"697_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/epi.16769","volume":"62","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, De Maria G, Rosati E, Didato G, Chiesa V, Ranzato F, et al. Brivaracetam as add-on treatment in focal epilepsy: a real-world time-based analysis. Epilepsia. 2021;62(1):e1\u20136.","journal-title":"Epilepsia"},{"issue":"12","key":"697_CR19","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1111\/epi.17087","volume":"62","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk A, Zaveta C, von Podewils F, M\u00f6ddel G, Langenbruch L, Kovac S, et al. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: a longitudinal multicenter study with up to 5 years of follow-up. Epilepsia. 2021;62(12):2994\u20133004.","journal-title":"Epilepsia"},{"key":"697_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106967","volume":"106","author":"J Adewusi","year":"2020","unstructured":"Adewusi J, Burness C, Ellawela S, Emsley H, Hughes R, Lawthom C, et al. Brivaracetam efficacy and tolerability in clinical practice: a UK-based retrospective multicenter service evaluation. Epilepsy Behav. 2020;106:106967.","journal-title":"Epilepsy Behav"},{"key":"697_CR21","unstructured":"Henninger H, Sperling MR, Altalib HH, Dave H, Gelfand M, Porter R, et al.: Effectiveness and tolerability of brivaracetam by reason for initiation in adults with focal seizures: post-hoc analysis of a real-world, US study (abstract 3.277). https:\/\/cms.aesnet.org\/abstractslisting\/effectiveness-and-tolerability-of-brivaracetam-by-reason-for-initiation-in-adults-with-focal-seizures--post-hoc-analysis-of-a-real-world--us-study (2021). Accessed 23 May 2022."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00697-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00697-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00697-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:31:00Z","timestamp":1741851060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00697-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["697"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00697-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bernhard J. Steinhoff has received honoraria for consulting from Angelini Pharma, B. Braun Melsungen, Desitin, Eisai, and UCB, for serving on a scientific advisory board from GW Pharmaceuticals, Precisis, UCB, and Zogenix, and for speaking from Arvelle, Desitin, Eisai, Hikma Pharmaceuticals, UCB, and Zogenix, and has received research support from Eisai, SK Life Science, and UCB. Jakob Christensen has received honoraria from serving on the scientific advisory board of Eisai AB and UCB, received honoraria for giving lectures from Eisai AB and UCB, and received funding for a trip from UCB. Colin P. Doherty has received honoraria from Eisai and UCB. Marian Majoie has received financial compensation through her institution for participating in contract research from Eisai, GW Pharmaceuticals, UCB, and Zogenix. Anne-Liv Schulz, Fiona Brock, Dimitrios Bourikas, and Iryna Leunikava are employees of UCB. Anne-Liv Schulz and Dimitrios Bourikas have received UCB stocks from their employment. Anna Kelemen has received honoraria for serving on advisory boards from Eisai and Zogenix, and has received honoraria for lectures and publications from GW Pharmaceuticals, Richter Gedeon, and UCB. Eduardo Rubio-Nazabal has received honoraria from BIAL, Eisai, and UCB for speaking.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was reviewed and approved by an Institutional Review Board\/Independent Ethics Committee (see Institutional Review Board\/Independent Ethics Committee appendix in the Supplementary Material), according to country-specific regulations. Written data consent was obtained from the patient, parent(s), or legal representative before study participation, in accordance with local regulations and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}